Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Biogen Inc.

Meirav Chovav of Salomon Brothers lowered her rating on Biogen Inc. to "hold" from "buy" because disappointing

Hirulog

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE